206 related articles for article (PubMed ID: 24492344)
1. Consequences of glycan truncation on Fc structural integrity.
Buck PM; Kumar S; Singh SK
MAbs; 2013; 5(6):904-16. PubMed ID: 24492344
[TBL] [Abstract][Full Text] [Related]
2. Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.
Lee HS; Im W
Sci Rep; 2017 Oct; 7(1):12659. PubMed ID: 28978918
[TBL] [Abstract][Full Text] [Related]
3. Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity.
Chen CL; Hsu JC; Lin CW; Wang CH; Tsai MH; Wu CY; Wong CH; Ma C
ACS Chem Biol; 2017 May; 12(5):1335-1345. PubMed ID: 28318221
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics simulation of the crystallizable fragment of IgG1-insights for the design of Fcabs.
Lai B; Hasenhindl C; Obinger C; Oostenbrink C
Int J Mol Sci; 2014 Jan; 15(1):438-55. PubMed ID: 24451126
[TBL] [Abstract][Full Text] [Related]
5. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
[TBL] [Abstract][Full Text] [Related]
6. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
Wormald MR; Rudd PM; Harvey DJ; Chang SC; Scragg IG; Dwek RA
Biochemistry; 1997 Feb; 36(6):1370-80. PubMed ID: 9063885
[TBL] [Abstract][Full Text] [Related]
7. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
8. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
9. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
Falconer DJ; Subedi GP; Marcella AM; Barb AW
ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
[TBL] [Abstract][Full Text] [Related]
10. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
11. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of deglycosylated human IgG4-Fc.
Davies AM; Jefferis R; Sutton BJ
Mol Immunol; 2014 Nov; 62(1):46-53. PubMed ID: 24956411
[TBL] [Abstract][Full Text] [Related]
13. Insights into substrate recognition and specificity for IgG by Endoglycosidase S2.
Aytenfisu AH; Deredge D; Klontz EH; Du J; Sundberg EJ; MacKerell AD
PLoS Comput Biol; 2021 Jul; 17(7):e1009103. PubMed ID: 34310592
[TBL] [Abstract][Full Text] [Related]
14. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
[TBL] [Abstract][Full Text] [Related]
15. Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis.
Bowden TA; Baruah K; Coles CH; Harvey DJ; Yu X; Song BD; Stuart DI; Aricescu AR; Scanlan CN; Jones EY; Crispin M
J Am Chem Soc; 2012 Oct; 134(42):17554-63. PubMed ID: 23025485
[TBL] [Abstract][Full Text] [Related]
16. CD16a with oligomannose-type
Subedi GP; Barb AW
J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin G1 Fc domain motions: implications for Fc engineering.
Frank M; Walker RC; Lanzilotta WN; Prestegard JH; Barb AW
J Mol Biol; 2014 Apr; 426(8):1799-811. PubMed ID: 24522230
[TBL] [Abstract][Full Text] [Related]
18. Impact of Fc N-glycan sialylation on IgG structure.
Zhang Z; Shah B; Richardson J
MAbs; 2019; 11(8):1381-1390. PubMed ID: 31411531
[TBL] [Abstract][Full Text] [Related]
19. Processing of complex N-glycans in IgG Fc-region is affected by core fucosylation.
Castilho A; Gruber C; Thader A; Oostenbrink C; Pechlaner M; Steinkellner H; Altmann F
MAbs; 2015; 7(5):863-70. PubMed ID: 26067753
[TBL] [Abstract][Full Text] [Related]
20. Influence of glycan modification on IgG1 biochemical and biophysical properties.
Pawlowski JW; Bajardi-Taccioli A; Houde D; Feschenko M; Carlage T; Kaltashov IA
J Pharm Biomed Anal; 2018 Mar; 151():133-144. PubMed ID: 29324282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
